RT Journal Article
SR Electronic
A1 Misra-Press, Anita
T1 TIME Trial
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 8
SP 11
OP 13
DO 10.1177/1559897715588311
UL http://mdc.sagepub.com/content/15/8/11.2.abstract
AB The phase 2b results of the randomized, double-blind, placebo-controlled TIME study provide evidence of activity with TG4010, a therapeutic cancer vaccine, when added to first-line chemotherapy for stage IV non–small cell lung cancer, especially for nonsquamous histology and low levels of triple-positive activated lymphocytes. These data suggest that normal levels of triple-positive activated lymphocytes may be a predictive biomarker of TG4010 efficacy.